<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04968379</url>
  </required_header>
  <id_info>
    <org_study_id>1VIT19046</org_study_id>
    <nct_id>NCT04968379</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, PK and PD of Intravenous Ferric Carboxymaltose in Infants With Iron Deficiency Anemia</brief_title>
  <official_title>An Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Ferric Carboxymaltose (FCM) in Infants (0-1 Year) With Iron Deficiency Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American Regent, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American Regent, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics and&#xD;
      Pharmacodynamics of Intravenous Ferric Carboxymaltose (FCM) in Infants (0-1 year) with Iron&#xD;
      Deficiency Anemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase II, open-label, multi-center inpatient study with 2 Cohorts to evaluate the safety,&#xD;
      tolerance, PK, and PD profile of intravenous (IV) FCM in infants 0 to 1 year of age with IDA&#xD;
      after receiving either a 5.0 mg/kg or 7.5 mg/kg dose of FCM.&#xD;
&#xD;
      Participants who satisfy the inclusion requirements and no exclusion criteria will be&#xD;
      eligible to participate in this study and enter into a screening phase to confirm&#xD;
      eligibility.&#xD;
&#xD;
      Participants will have a screening evaluation within 14 days of the first dose of study drug.&#xD;
      A medically supervised environment is required on Day 1 (day of dosing) and for 24 hours post&#xD;
      dosing (and completion of all Day 2 study procedures). Outpatient participants will be&#xD;
      admitted to the hospital (or clinical study unit) on the day of dosing (Day 1). Patients&#xD;
      hospitalized are allowed to be enrolled if satisfying the inclusion and exclusion criteria.&#xD;
      Participants will return to the study site for additional evaluation and sampling on Days 8&#xD;
      (± 2 days), 15 (± 2 days), 22 (± 2 days), and 36 (± 2 days).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2021</start_date>
  <completion_date type="Anticipated">September 12, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 8, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-emergent adverse events</measure>
    <time_frame>Baseline to Day 36</time_frame>
    <description>Treatment-emergent clinical laboratory test (clinical chemistry and hematology) abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hemoglobin (Hb): g/dL</measure>
    <time_frame>baseline to Days 8, 15, 22, and 36</time_frame>
    <description>determine appropriate dosing of FCM in infants from 0 to 1 year of age by evaluating PD parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in reticulocytes count: %</measure>
    <time_frame>baseline to Days 8, 15, 22, and 36</time_frame>
    <description>determine appropriate dosing of FCM in infants from 0 to 1 year of age by evaluating PD parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the PD parameters - Change in serum iron: mcg/dL</measure>
    <time_frame>baseline to Day 36</time_frame>
    <description>To determine appropriate dosing of FCM in infants from 0 to 1 year of age by evaluating PD parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the PD parameters - Change in serum ferritin: ng/mL</measure>
    <time_frame>baseline to Day 36</time_frame>
    <description>Description: To determine appropriate dosing of FCM in infants from 0 to 1 year of age by evaluating PD parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the PD parameters - Change in total iron binding capacity [TIBC]): mcg/dL</measure>
    <time_frame>baseline to Day 36</time_frame>
    <description>Description: To determine appropriate dosing of FCM in infants from 0 to 1 year of age by evaluating PD parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the PD parameters - Change in serum transferrin saturation [TSAT]): mg/dL</measure>
    <time_frame>baseline to Day 36</time_frame>
    <description>Description: To determine appropriate dosing of FCM in infants from 0 to 1 year of age by evaluating PD parameters.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Iron Deficiency, Anaemia</condition>
  <arm_group>
    <arm_group_label>Ferric Carboxymaltose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To evaluate the safety, tolerance, PK and PD profile of intravenous (IV) FCM in infants 0 to 1 year of age with IDA after receiving a 5.0 mg/kg dose of FCM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Injectafer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To evaluate the safety, tolerance, PK and PD profile of intravenous (IV) FCM in infants 0 to 1 year of age with IDA after receiving a 7.5 mg/kg dose dose of FCM.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric carboxymaltose</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Ferric Carboxymaltose</arm_group_label>
    <arm_group_label>Injectafer</arm_group_label>
    <other_name>Injectafer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female participants 0 to 1 year of age, medically indicated for iron&#xD;
             replacement, with his/her parent or legal guardian willing and able to sign the&#xD;
             informed consent form approved by the IRB / Independent Ethics Committee (IEC).&#xD;
&#xD;
          2. Screening Hb ≥7 g/dL to &lt;10 g/dL.&#xD;
&#xD;
          3. Infants with any of the following conditions:&#xD;
&#xD;
               -  Heart failure with IDA defined as syndromes of excessive preload, excessive&#xD;
                  afterload, abnormal rhythm, or decreased contractility&#xD;
&#xD;
               -  Gastrointestinal diseases with acquired short bowel syndrome (due to volvulus,&#xD;
                  necrotizing enterocolitis from surgical resection or spontaneous intestinal&#xD;
                  perforation)&#xD;
&#xD;
               -  Gastrointestinal intolerance of oral iron or an unsatisfactory response to oral&#xD;
                  iron&#xD;
&#xD;
               -  Other conditions associated with IDA which in the opinion of the investigator&#xD;
                  might benefit from administration of FCM&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known history of hypersensitivity reaction to FCM.&#xD;
&#xD;
          2. Body weight &lt;2.5 kg.&#xD;
&#xD;
          3. History of acquired iron overload, hemochromatosis, or other iron accumulation&#xD;
             disorders.&#xD;
&#xD;
          4. Hemodialysis-dependent chronic kidney disease.&#xD;
&#xD;
          5. History of significant diseases of the liver, hematopoietic system, cardiovascular&#xD;
             system, or other conditions which, on the opinion of the investigator, may place a&#xD;
             participant at added risk for participation in the study.&#xD;
&#xD;
          6. Active infection.&#xD;
&#xD;
          7. Anemia due to reasons other than iron deficiency (e.g., hemoglobinopathy vitamin B12&#xD;
             deficiency, or folic acid deficiency).&#xD;
&#xD;
          8. Blood transfusion in the 4 weeks prior to consent.&#xD;
&#xD;
          9. Administration of an iron-containing product within 14 days of administration of the&#xD;
             study article.&#xD;
&#xD;
         10. Administration and / or use of an investigational product (drug or device) within 30&#xD;
             days of screening.&#xD;
&#xD;
         11. Current participation in another clinical trial.&#xD;
&#xD;
         12. Unable to comply with study procedures and assessments.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Falone, MD</last_name>
    <role>Study Director</role>
    <affiliation>American Regent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Falone, MD</last_name>
    <phone>16318168908</phone>
    <phone_ext>61844</phone_ext>
    <email>MFalone@americanregent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cohen Children's Medical Center</name>
      <address>
        <city>Queens</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Barry I Weinberger, MD</last_name>
      <phone>718-470-3440</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>July 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

